CORAL GABLES, FL / ACCESSWIRE / October 16, 2015 / A report from ReporterLink (http://www.reportlinker.com/p03185388-summary/view-report.html) recently analyzed the biotechnology industry including the outlying differences between biotech and pharma companies. Furthermore the report highlighted that despite the growth emerging markets like China, Brazil, and India are realizing in sales growth, the Americas and Europe hold the largest share in the global biotech industry with a 45% and 30% share respectively.
Even though biotech stocks have hit a rough patch in recent months, many analysts are still calling for potential in the sector. Rajiv Kaul, manager of Fidelity(R) Select Biotechnology Portfolio, has observed this market and thinks that many may be misreading the potential impact certain risks could have on biotech stocks. He has been using the recent pullback as an opportunity to upgrade the quality of the names in his fund. In a recent interview with Forbes he states that he still believes that biotech's five-to-10-year investment story remains compelling and with that, many biotech companies have bucked this trend while offering more for investors. Companies like SciVac Therapeutics Inc. (OTCQX: SVACF), Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), and Transition Therapeutics Inc. (NASDAQ: TTHI) have seen increases in price and volume over recent weeks.
Earlier this year SciVac announced that it had completed its transaction and was granted approval by the Toronto Stock Exchange following a restructuring by Opko Health CEO Dr. Phillip Frost. Since then the company has been focused on the further development of its Hepatitits B vaccine called Sci-B-Vac. This drug is a third generation vaccine that contains 3 hep B surface antigens. This difference in comparison to other second generation vaccines has shown to improve vaccine response. In two comparative studies Sci-B-Vac demonstrated that it produced sero-protection, which offers protection from the virus itself. The third generatio has shown efficacy in more than 20 company sponsored trials across 5000 individuals and is already approved in 10 countries. Over the last week shares of SVACF have increased to as high as $0.195 as well as have seen an overall increase in trading volume. The stock closed Thursday at $0.189.
Earlier this week Peregrine Pharmaceuticals announced that it has expanded its ongoing cancer immunotherapy clinical collaboration with AstraZeneca to include a later stage trial to evaluate the immunotherapy combination of Peregrine's phosphatidylserine-targeted immune activator, bavituximab, along with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor, duryalumab, in a global Phase II study. The patients participating in the study will have previously been treated for squamous or non-squamous non-small cell lung cancer. The announcement spurred a jump in share price from Wednesday's close of $1.04 to a high on Thursday of $1.11.
Transition Therapeutics announced yesterday that its subsidiary, Transition Therapeutics Ireland Limited had completed full review of the data pertaining to its Phase 2/3 study of ELND005 for Alzheimer's disease in patients with moderate or severe agitation and aggression. The study demonstrated that ELND005 met acceptable safety and tolerability profiles as well as numerical improvement in 20 of the 21 symptoms measured as part of its main efficacy endpoint. Shares of TTHI jumped from an open of $2.30 to highs of $2.75 before closing at $1.99 on Thursday afternoon.
About Biotech Stocks (www.BiotechStocks.com)
Biotech Stocks (www.biotechstocks.com) is your best resource for today's emerging biotech industry. Whether you're looking for the best biotech stocks to buy, biotech news, trends in biotech, articles within the biotech industry and so much more, BiotechStocks.com is your destination for it all. Our goal is to become the central hub for all who are seeking current Biotech Stock News as well as biotech industry, political and social news, articles, trends & overall insight, delivered in a way that we all can relate to.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. BiotechStocks.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. BiotechStocks.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. BiotechStocks.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Please view full disclaimer at http://www.biotechstocks.com/disclaimer for more details
Contact Info:
Email: info@biotechstocks.com
URL: www.BiotechStocks.com
SOURCE: BioTechStocks.com
